Startups
Slayback Pharma LLC is a specialty pharmaceutical company focused on developing, manufacturing and sourcing of complex generic pharmaceutical products, with a specific emphasis on complex injectables and other non-solid oral products. Slayback has created a unique portfolio of complex generics by smart product selection and execution and connecting various dots through a network of contract R&D laboratories and manufacturing organizations, comprising smart and rapid development capabilities, sophisticated manufacturing and innovative drug delivery technologies.
Overview
Location
United States, New Jersey, West Windsor
Employees
51-200
Total raised
$110M
Founded date
2011
Investors 1
| Date | Name | Website |
| Sign up to see | Sign up to see | Sign up to see |
Funding Rounds 2
| Date | Series | Amount | Investors |
| Sign up to see | Sign up to see | Sign up to see | Sign up to see |
| Jan 5, 2017 | Funding round | $60M | Kohlberg Kravis Roberts |
Mentions in press and media 10
| Date | Title | Description |
| Sign up to see | Sign up to see | Sign up to see |
| Feb 4, 2021 | Slayback Pharma announces launch of Merzee (norethindrone acetate and ethinyl estradiol capsules and ferrous fumarate capsules) 1 mg/20 mcg, generic equivalent of Taytulla® | |
| Dec 18, 2020 | Slayback Pharma announces FDA approval of Merzee, generic equivalent of Taytulla® with a Competitive Generic Therapy (CGT) Designation | |
| Dec 7, 2020 | Slayback Pharma Appoints Dr Sumitra Pillai as Head of R&D | |
| Aug 17, 2020 | Slayback Pharma Appoints Lori A. Hoffman as Head of Alliance Management | |
| Jan 6, 2020 | Everstone Group signs pact to invest $50m in Slayback Pharma | Premium New Jersey-based Slayback Pharma has entered into an agreement to raise $50 million in its Series B round of funding from private equity firm The Everstone Group, per an announcement on Monday. Continue reading this story with a sub... |
| Jan 6, 2020 | Slayback Pharma Raises $50M in Series B | PRINCETON, NJ, Slayback Pharma announced an agreement with The Everstone Group to invest up to US$50 million in Series B funding. >> Click here for more funding data on Slayback Pharma >> To export Slayback Pharma funding da... |
| Jan 9, 2017 | Former Dr. Reddy’s exec-led Slayback Pharma raises $60 mn from KKR | Slayback Pharma, LLC, a privately held pharmaceutical company founded by a former executive of Indian drugmaker Dr. Reddy's Laboratories Ltd, has raised $60 million (around Rs 400 crore) from global investment firm KKR, it said in a stateme... |
| Jan 5, 2017 | Slayback Pharma Announces $60 Million in New Financing by KKR | PRINCETON JUNCTION, N.J.--(BUSINESS WIRE)-- Slayback Pharma, LLC ("Slayback"), a privately held pharmaceutical research and development company, announced today the closing of a $60 million commitment by KKR, a leading global in... |
| Jan 5, 2017 | Term Sheet — Thursday, January 5 | THE 21 BEST TECH IPOS of 2016, ETC Visions: SoftBank has been purposely opaque about many aspects of Vision Fund, its $100 billion (!) tech investment fund, in part, because the fund isn’t closed yet and general solicitation rules prevent i... |
Reviews 0
FAQ about Slayback Pharma
When was Slayback Pharma founded?
Slayback Pharma was founded in 2011.
How much funding has Slayback Pharma raised?
Slayback Pharma has raised $110M in total across 2 funding rounds.
What funding rounds has Slayback Pharma raised?
Parsers VC lists 2 funding rounds of Slayback Pharma, among them a funding round of $60M on Jan 5, 2017.
What has the press written about Slayback Pharma?
Parsers VC has collected 10 articles mentioning Slayback Pharma, among them “Slayback Pharma announces launch of Merzee (norethindrone acetate and ethinyl estradiol capsules and ferrous fumarate capsules) 1 mg/20 mcg, generic equivale...” (Feb 4, 2021) and “Slayback Pharma announces FDA approval of Merzee, generic equivalent of Taytulla® with a Competitive Generic Therapy (CGT) Designation” (Dec 18, 2020).
Is Slayback Pharma still active?
Yes, Slayback Pharma is active; its latest activity on Parsers VC dates from Jun 25, 2021.